EPP Case Review: Protoporphyrin Levels 6x Symptom Threshold, Liver Intact

Erythrocyte protoporphyrin levels averaging 3,100 to more than 6,000 micrograms per deciliter — against a symptom threshold of roughly 500 — mark Mr. Willis's erythropoietic protoporphyria as severe disease. That is the headline number from the final installment of the Dermatology Times Case-Based Peer Perspectives series, in which Dr. Bonkovsky reviews the laboratory and imaging record and asks the patient why he stayed in clinical trials.

What do the labs actually show?

The numbers tell a consistent story. Erythrocyte protoporphyrin has run between 3,100 and over 6,000 mcg/dL over time, far above the approximately 500 mcg/dL typically required for symptoms. Plasma protoporphyrin has also stayed high — consistent with severe disease, since most patients never reach the 14 to 21 range he has recorded.

The hematology panel adds texture:

• Chronically low white blood cell count
• Mildly low platelets
• Mild splenomegaly
• Low ferritin
• Low transferrin saturation

Photosensitivity in EPP tracks not just protoporphyrin production but how effectively the liver clears it. That is why Dr. Bonkovsky stresses hepatitis A and B vaccination, minimal alcohol, and avoidance of cholestatic drugs for these patients — hepatic clearance is the lever clinicians can actually protect.

How has the liver held up?

Remarkably well. FibroScan stiffness has remained normal, and a biopsy taken during Mr. Willis's acute episode looked relatively normal. No cirrhosis. Liver fat did rise on FibroScan, but it improved with weight loss. He continues on bitopertin through expanded access — a practical point for anyone managing EPP patients who finish a trial but still need the drug.

Why skip an approved therapy?

Dr. Bonkovsky asks the obvious question: why did Mr. Willis never take afamelanotide after approval? Two reasons. Accessibility first — approved clinics are simply far away. And second, he wanted to stay in the testing process to help the children who come after him. That answer frames the whole series: research participation as a forward-looking act, not just personal treatment.

What does the family picture tell us?

EPP generally requires two abnormal alleles. Mr. Willis's wife is unaffected, and none of his children or grandchildren has symptoms. All three biological children were tested; one daughter carries only the minor ferrochelatase variant. The family history reaches back further — Mr. Willis recalls a great-uncle, a farmer whose hands swelled and split in the sun, never diagnosed in his lifetime.

What does this change for clinicians?

Three takeaways for practice. Track erythrocyte and plasma protoporphyrin longitudinally, because the magnitude predicts severity and most patients never reach this patient's plasma range. Protect the liver aggressively — vaccination, alcohol counseling, cholestatic drug avoidance — because clearance drives photosensitivity. And keep expanded access and trial participation on the table as viable pathways when approved options are geographically out of reach.

Dr. Bonkovsky thanked Mr. Willis for his willingness to join trials, which advance the field and bring new treatments to the clinic. Mr. Willis returned the thanks, crediting Dr. Bonkovsky and other researchers who started so long ago: he does not know where patients would be without them. For a disease this rare, that exchange between one long-studied patient and one long-committed investigator is roughly how the therapeutic landscape gets built.